Centre for Evolution and Cancer (CEC)'s Avatar

Centre for Evolution and Cancer (CEC)

@cec-icr.bsky.social

Evolution and cancer research @icrlondon.bsky.social. Interests include: drug resistance pre-malignancy and early detection epigenetics plasticity population genetics microbiome lineage tracing biotech Director @trevorgraham.bsky.social

371 Followers  |  27 Following  |  2 Posts  |  Joined: 11.11.2024  |  1.5079

Latest posts by cec-icr.bsky.social on Bluesky

Adaptive Therapy Abstract. A number of successful systemic therapies are available for treatment of disseminated cancers. However, tumor response is often transient, and therapy frequently fails due to emergence of re...

Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper:
aacrjournals.org/cancerres/ar...

& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social

02.05.2025 12:58 β€” πŸ‘ 2    πŸ” 1    πŸ’¬ 0    πŸ“Œ 0

In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer.

We eagerly await the clinical trial results - they will be definitive.

02.05.2025 12:52 β€” πŸ‘ 3    πŸ” 1    πŸ’¬ 2    πŸ“Œ 0
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha... Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...

This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...

02.05.2025 12:50 β€” πŸ‘ 4    πŸ” 2    πŸ’¬ 1    πŸ“Œ 0
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...

With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped.
aacrjournals.org/cancerres/ar...

@icr.ac.uk @qmbci.bsky.social

02.05.2025 12:43 β€” πŸ‘ 36    πŸ” 6    πŸ’¬ 2    πŸ“Œ 0

Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.

05.12.2024 20:24 β€” πŸ‘ 11    πŸ” 5    πŸ’¬ 1    πŸ“Œ 0

Frequent evolution of BRCA2 reversion mutations during PARPi treatment in prostate cancer

22.11.2024 09:29 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Welcome to #bsky @alejandrapcelab.bsky.social ! Alejandra Bruna leads the paediatric cancer evolution (PCE) lab here in our @cec-icr.bsky.social. Focusing on dissecting the role of phenotypic plasticity in childhood cancer evolution and therapy response.

21.11.2024 14:58 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

@cec-icr is following 20 prominent accounts